Skip to main content
. 2009 Mar 27;338:b919. doi: 10.1136/bmj.b919

Table 1.

 Sensitivity and subgroup analyses for relative risk (RR) of all cause mortality during infancy

Stratification variable* No of trials RR (95% CI); P value Tests for heterogeneity I2 (%); Q (P value) P value for heterogeneity in subgroups
Random effects model Fixed effects model
Overall 6 0.92 (0.75 to 1.12); 0.393 0.90 (0.80 to 1.02); 0.090 54.1; 10.90 (0.053) NA
Attrition:
 <10% 4 0.89 (0.77 to 1.03); 0.119 0.89 (0.78 to 1.01); 0.065 14.8; 3.52 (0.318)
 ≥10% 2 0.71 (0.21 to 2.36); 0.576 1.01 (0.72 to 1.42); 0.939 85.4; 6.84 (0.009) 0.465
Follow-up age (months):
 ≤6 3 0.85 (0.73 to 0.98); 0.024 0.85 (0.73 to 0.98); 0.024 0.0; 1.63 (0.444)
 >6 3 0.92 (0.57 to 1.48); 0.715 1.05 (0.83 to 1.31); 0.703 71.0; 6.9 (0.032) 0.123
Maternal postpartum vitamin A supplementation (≥30% mothers):
 No 4 0.85 (0.63 to 1.16); 0.305 0.86 (0.73 to 1.01); 0.062 61.2; 7.72 (0.052)
 Yes 2 1.01 (0.73 to 1.40); 0.961 0.96 (0.80 to 1.16); 0.676 58.1; 2.39 (0.122) 0.374
No of vitamin A doses received:
 Single 5 0.96 (0.76 to 1.23); 0.767 0.97 (0.83 to 1.12); 0.659 51.4; 8.23 (0.083)
 Multiple 1 0.78 (0.63 to 0.96); 0.021 0.78 (0.63 to 0.96); 0.021 NA 0.102
Maternal night blindness:
 <5% 1 1.24 (0.85 to 1.79); 0.262 1.24 (0.85 to 1.79); 0.262 NA
 ≥5% 2 0.83 (0.71 to 0.96); 0.014 0.83 (0.71 to 0.96); 0.014 0.0; 0.61 (0.433) 0.049
Birth weight specific†:
 Low birth weight 3 0.76 (0.58 to 1.01); 0.056 0.80 (0.69 to 0.93); 0.003 52.7; 4.23 (0.121) 0.380
 Other 3 0.78 (0.43 to 1.40); 0.399 0.92 (0.70 to 1.20); 0.514 63.7; 5.50 (0.064)

NA= not applicable.

*Not done for allocation concealment, blinding, trial site, maternal serum retinol and cumulative vitamin A dose received by neonate as all trials were categorised in only one of two strata.

†Restricted to trials depicting results separately for low and non-low birthweight infants. For these data, in Klemm 2008w14 maternal supplementation with either β carotene or synthetic vitamin A had also been given in comparison (placebo) group according to randomised allocation in this nested design.